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Abstract
High plasma osteoprotegerin (OPG) and asymmetric dimethylarginine (ADMA) and low homoarginine (hArg) predict 
adverse renal and cardiovascular (CV) outcomes. In patients with chronic kidney disease and stable coronary artery disease, 
plasma OPG correlated with hArg (r = − 0.37, P = 0.03) and the hArg/ADMA molar ratio (r = − 0.46, P = 0.009), which 
was maintained upon adjustment for renal function. Elevated OPG levels and decreased hArg/ADMA ratios independently 
predicted 4-year composite CV and renal endpoints (CV death or progression to dialysis). Thus, high OPG and low hArg/
ADMA ratio, albeit interrelated, appear to independently contribute to adverse clinical outcome.
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Abbreviations
ADMA  Asymmetric dimethylarginine
AGAT  l-Arginine:glycine amidinotransferase
CAD  Coronary artery disease
CKD  Chronic kidney disease
CV  Cardiovascular
∆eGFR  eGFR change
eGFR  Estimated glomerular filtration rate
hArg  l-Homoarginine
NO  Nitric oxide
NOS  Nitric oxide synthase
OPG  Osteoprotegerin
Introduction
Osteoprotegerin (OPG) is expressed by osteoblasts, 
cytokine-activated endothelia, vascular myocytes and mac-
rophages and predicts adverse cardiovascular (CV) outcome 
in the general population (Kiechl et al. 2004; Semb et al. 
2009; Lieb et al. 2010; Tschiderer et al. 2017) and in various 
clinical settings (Tschiderer et al. 2018), including patients 
with chronic kidney disease (CKD) (Mesquita et al. 2009; 
Lewis et al. 2015; Kuźniewski et al. 2016; Yilmaz et al. 
2016), stable coronary artery disease (CAD) (Bjerre et al. 
2014) and acute coronary syndromes (Røysland et al. 2012). 
Elevated OPG levels are also associated with future rapid 
renal function decline in elderly women (Lewis et al. 2014) 
and progression to end-stage renal-disease in type 1 diabetes 
mellitus (Jorsal et al. 2008). OPG affects numerous intracel-
lular pathways that modulate activation and propensity to 
apoptosis (Venuraju et al. 2010).
In subjects with CAD (Morisawa et al. 2015) and essen-
tial hypertension (Tsioufis et al. 2011), OPG correlated 
positively with asymmetric dimethylarginine (ADMA), 
a recognized predictor of CV risk (Böger et al. 2009) and 
CKD progression (Fliser et al. 2005; Ravani et al. 2005). 
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ADMA originates from the proteolysis of proteins methyl-
ated on Arg residues by protein arginine methyltransferase 
1 (PRMT1; EC 2.1.1.125). hArg is primarily of renal origin 
and is biosynthesized by l-arginine:glycine amidinotrans-
ferase (AGAT; EC 2.1.4.1). To the best of our knowledge, no 
studies have dealt with relations of OPG and l-homoarginine 
(hArg), an emerging risk factor in the renal and CV systems 
(März et al. 2010; Atzler et al. 2013, 2014; Choe et al. 2013; 
Drechsler et al. 2013; Kleber et al. 2013; Ravani et al. 2013; 
Pilz et al. 2014; Frenay et al. 2015; Kayacelebi et al. 2017; 
Zinellu et al. 2018).
Associations of CV mortality risk with high OPG (Lewis 
et al. 2015) or low hArg (Tomaschitz et al. 2014) concentra-
tions are considerably stronger in subjects with an estimated 
GFR (eGFR) below 60 mL/min/1.73 m2. We, therefore, 
hypothesized that the kidneys may play a major role both 
in the homeostasis and modulation of biological effects of 
hArg and OPG in CKD patients with CAD. The primary 
aim of the present study was to test for mutual associations 
between OPG, hArg and ADMA in plasma of patients with 
CKD and CAD. We also tested a potential prognostic value 
of OPG with regard to 1-year renal function decline and 
4-year clinical outcome in patients with both CAD and pre-
dialysis CKD.
Methods
Patients
Forty men with CKD were recruited from non-smoking 
patients admitted to the Second Department of Cardiol-
ogy of Jagiellonian University Medical College for elective 
coronary angiography for stable CAD (Table 1). All CKD 
subjects were free of heart failure, left ventricular systolic 
dysfunction (ejection fraction ≥ 50% by echocardiography), 
clinical instability or coexistent diseases except for well-
controlled type 2 diabetes mellitus or hypertension. Patients 
Table 1  Patients’ characteristics and plasma concentrations of biochemical parameters according to 1-year GFR change (∆eGFR) and 4-year 
composite clinical outcome
Data are shown as mean ± SD or median [interquartile range]
hs-CRP high-sensitive C reactive protein, MDA malondialdehyde
a Statistically significant intergroup differences are marked in bold
Characteristic 1-year eGFR changes (∆eGFR) P Progression to dialysis or death within 
4 years
P
< Median > Median Progressors Non-progressors
Age (years) 67 ± 11 59 ± 17 NS 67 ± 10 60 ± 16 NS
Hypertension n (%) 19 (95%) 17 (85%) NS 12 (80%) 24 (96%) NS
Diabetes n (%) 7 (21%) 7 (21%) NS 5 (33%) 9 (36%) NS
eGFR (mL/min/1.73 m2) 29 ± 19 37 ± 28 NS 25 ± 18 38 ± 24 0.08
∆eGFR (mL/min/1.73 m2) − 4.3 ± 2.5 8.7 ± 11.4 < 0.001a − 1.8 ± 5.3 5.2 ± 11.9 0.04a
BMI (kg/m2) 28.7 ± 3.8 27.7 ± 3.6 NS 28.1 ± 2.7 28.4 ± 3.9 NS
Hemoglobin (g/dL) 12.0 ± 2.1 13.4 ± 1.8 NS 11.7 ± 2.0 13.2 ± 1.9 NS
LDL-cholesterol (mM) 2.2 ± 0.7 2.4 ± 0.8 NS 2.3 ± 0.7 2.4 ± 0.6 NS
HDL-cholesterol (mM) 1.2 ± 0.3 1.3 ± 0.3 NS 1.2 ± 0.2 1.4 ± 0.3 NS
Triglycerides (mM) 1.5 ± 0.5 1.7 ± 0.5 NS 1.6 ± 0.6 1.6 ± 0.5 NS
hs-CRP (mg)/L 3.8 [1.6–5.9] 2.9 [0.9–5.4] NS 4.5 [1.6–5.4] 2.9 [0.9–5.1] NS
Calcium (mM) 2.2 ± 0.2 2.4 ± 0.2 NS 2.2 ± 0.3 2.3 ± 0.1 NS
Phosphate (mM) 1.1 ± 0.2 1.2 ± 0.2 NS 1.2 ± 0.2 1.1 ± 0.2 NS
Osteoprotegerin (μg/L) 2.7 [2.5–3.0] 2.1 [1.6–3.5] 0.07 3.0 [2.5–3.9] 1.9 [1.6–2.7] 0.002a
Arg (μM) 245 [178–408] 294 [274–396] NS 352 [260–521] 278 [210–299] 0.06
ADMA (μM) 0.63 [0.58–0.75] 0.60 [0.54–0.74] NS 0.73 [0.61–0.78] 0.60 [0.55–0.64] 0.08
Arg/ADMA ratio 388 [262–626] 517 [424–655] NS 468 [293–706] 448 [337–609] NS
hArg (μM) 0.99 [0.67–1.46] 1.19 [0.62–2.05] NS 0.97 [0.67–1.29] 1.34 [0.60–1.93] NS
Arg/hArg ratio 261 [144–429] 280 [150–483] NS 344 [248–595] 204 [121–422] 0.06
hArg/ADMA ratio 1.82 [1.19–2.28] 1.60 [1.17–3.30] NS 1.31 [1.09–1.76] 2.28 [1.30–3.15] 0.025a
Nitrite (μM) 2.47 [2.12–2.86] 2.40 [2.12–2.74] NS 2.52 [2.20–2.76] 2.40 [2.07–2.98] NS
Nitrate (μM) 83 [58–119] 87 [66–115] NS 72 [57–108] 87 [68–118] NS
MDA (μM) 1.40 [0.96–1.59] 0.93 [0.74–1.39] NS 1.11 [0.92–3.01] 1.05 [0.70–1.58] NS
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with relevant abnormalities in routine blood assays or with 
prehospital evidence of unstable creatinine levels were 
excluded. All patients were on a standard medical therapy 
recommended by practice guidelines, including low-dose 
aspirin, statins and angiotensin-converting enzyme inhibi-
tors for at least 3 months prior to the index hospitalization. 
CKD diagnosis was based on an eGFR value between 15 and 
59 mL/min/1.73 m2 by the CKD-EPI formula, corresponding 
to eGFR stages G3–G4 according to 2011 KDIGO classifi-
cation of CKD (Levey et al. 2011).
Follow-up data were collected during routine control vis-
its in our outpatient clinic, including control creatinine assay 
performed 12 ± 1 months after discharge. Patients or their 
relatives were contacted by telephone for the occurrence of 
a 4-year composite adverse clinical outcome, i.e., combined 
progression to dialysis or death from a CV cause, which was 
then confirmed by the review of medical records.
The study was approved by the Bioethics Commit-
tee of the Jagiellonian University (ethical approval No. 
KBET/364/B/2012) in adherence to the Declaration of Hel-
sinki. All participants provided written informed consent.
Biochemical analyses
OPG, hArg, ADMA and other biomarkers were measured in 
available EDTA plasma samples (n = 36, 35 and 32 for OPG, 
hArg and ADMA, respectively). OPG was measured by an 
enzyme immunoassay (R&D Systems, Minneapolis, MN, 
USA). LDL and HDL cholesterol, triglycerides, hemoglobin, 
creatinine and high-sensitive C-reactive protein (hs-CRP) 
were determined by standard clinical chemistry laboratory 
assays. Amino acids, malondialdehyde (MDA), nitrite and 
nitrate were analyzed by fully validated gas chromatography-
mass spectrometry (GC–MS) methods as described previ-
ously (Tsikas 2017; Hanff et al. 2017, 2019).
Statistical analysis
Data are presented as mean ± SD, median [interquartile 
range: 25th–75th percentile] or numbers and percentages. 
Normality was evaluated by Shapiro–Wilk’s test. Patients’ 
characteristics were compared according to the 1-year eGFR 
change (∆eGFR), dichotomized with the reference to the 
median value of − 0.9 mL/min/1.73 m2, or to a 4-year pro-
gression to dialysis or CV death. Intergroup differences in 
continuous data were estimated by two-tailed Student’s t 
test (or Welch’s t test in case of inhomogeneous variances 
assessed by Levene’s test) with prior decadic logarithmic 
 (log10) transformation; proportions were compared by Chi-
squared test. Bivariate Pearson’s correlation coefficients 
(rP) were calculated. Multiple logistic regression was used 
to estimate mutual independence of prognosticators with 
regard to the prediction of the progression to dialysis or 
the occurrence of CV death during a 4-year follow-up. 
Two-tailed P values < 0.05 were considered statistically 
significant.
Results
The concentrations of the biomarkers measured in the 
plasma samples of the study’s patients are summarized in 
Table 1. The relationships between OPG, hArg and ADMA 
are illustrated in Fig. 1.
Baseline plasma cocentrations of hArg and OPG cor-
related negatively with each other (rP = − 0.371, P = 0.03; 
Fig. 1a), which was maintained upon adjustment for eGFR. 
In contrast, baseline ADMA and OPG levels were posi-
tively correlated (rP = 0.385, P = 0.03; Fig. 1b). The hArg/
ADMA molar ratio correlated inversely with plasma OPG 
(rP = − 0.46, P = 0.009; Fig. 1c). ADMA and hArg concen-
trations were unrelated (rP = − 0.243, P = 0.187).
Six patients progressed to dialysis and nine died from 
CV causes over the subsequent 4 years. In these 15 patients 
(progressors), plasma OPG concentration was higher (3.0 
[2.5–3.9] vs. 1.9 [1.6–2.7] μg/L, P = 0.002) and the hArg/
ADMA molar ratio was lower (1.31 [1.09–1.76] vs. 2.28 
[1.30–3.15], P = 0.025) compared to the remainder (non-
progressors) (Table 1). Neither hArg nor ADMA plasma 
concentrations differed statistically significantly between 
progressors and non-progressors (Table 1). One-year eGFR 
decline was more pronounced in patients who developed 
future CV or renal endpoints (P = 0.04) (Table 1).
Multiple logistic regression revealed that higher OPG 
concentrations and lower hArg/ADMA ratios independently 
predicted 4-year composite CV and renal endpoints. Mean 
adjusted odds ratio for the adverse outcome was 1.30 [95% 
confidence interval, 1.03–1.64] (P = 0.02) per 1-μg/L incre-
ment in OPG and 0.3 [0.1–0.9] (P = 0.03) per 1-unit increase 
in the hArg/ADMA molar ratio (Hosmer–Lemeshow good-
ness-of-fit test, P = 0.3).
Discussion
To the best of our knowledge, a relationship between hArg 
and OPG has not been reported so far. Thus, our small study 
supplements previous observations of a positive correlation 
of OPG and ADMA in CAD (Morisawa et al. 2015) and 
essential hypertension (Tsioufis et al. 2011).
The patients’ plasma OPG concentrations were within 
reported ranges (Bjerre et al. 2014; Lewis et al. 2014), 
hArg levels were lower compared to healthy men or 
women (Kayacelebi et al. 2014a, b; Atzler et al. 2016), 
while ADMA was higher than in CAD patients (Thum 
et al. 2005). The hArg/ADMA molar ratio was lower in our 
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study group versus healthy subjects (Tsikas and Kayacel-
ebi 2014). Plasma nitric oxide (NO) metabolites nitrite and 
nitrate and the lipid peroxidation biomarker MDA were 
within references ranges reported previously (Hanff et al. 
2017; Tsikas 2017). As ADMA and hArg are formed from 
Arg in distinctly different pathways involving PRMT1 and 
AGAT, respectively, our observations suggest diminished 
AGAT activity, elevated PRMT1 activity, unaltered NOS 
activity and lipid peroxidation in our patients.
Given that elevated OPG, higher ADMA and lower hArg 
are established risk factors for renal and CV morbidity and 
mortality, it may suggest their synergistic contribution to the 
risk in patients with CKD and coexistent CAD via different 
detrimental pathways in the kidney and the vasculature. That 
high OPG and low hArg/ADMA molar ratio independently 
predicted the composite adverse clinical outcome and their 
mutual relationship was maintained upon adjustment for 
eGFR suggests that these prognostic effects were not entirely 
due to the association of abnormal levels of the biomark-
ers with impaired renal function (Fliser et al. 2005; Ravani 
et al. 2005, 2013; März et al. 2010; Røysland et al. 2012; 
Drechsler et al. 2013; Lewis et al. 2014).
Thus, high OPG and low hArg/ADMA ratio, albeit 
interrelated, appear to independently contribute to adverse 
clinical outcome. Admittedly, the underlying mechanisms 
connecting OPG with hArg and ADMA are still unresolved 
owing to their multiple, as yet not fully elucidated biologi-
cal actions. The intriguing findings of our small preliminary 
study warrant further validation in large cohorts.
Acknowledgements This work was supported by Jagiellonian Univer-
sity Medical College (research Grant no. K/ZDS/006105 to A.S.). The 
funding source had no involvement in study design, in the collection, 
analysis and interpretation of data, in the writing of the report, and in 
the decision to submit the article for publication.
Compliance with ethical standards 
Conflict of interest The authors declare that there no conflicts of inter-
est.
Ethical approval The study was approved by the Bioethics Committee 
of the Jagiellonian University (ethical approval no. KBET/364/B/2012) 
in adherence to the Declaration of Helsinki.
Informed consent All participants provided written informed consent.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
Atzler D, Rosenberg M, Anderssohn M, Choe CU, Lutz M, Zugck 
C, Böger RH, Frey N, Schwedhelm E (2013) Homoarginine—an 
independent marker of mortality in heart failure. Int J Cardiol 
168:4907–4909
Atzler D, Gore MO, Ayers CR, Choe CU, Böger RH, de Lemos 
JA, McGuire DK, Schwedhelm E (2014) Homoarginine and 
Fig. 1  Relationships between the plasma concentrations of OPG, 
hArg and ADMA in the study’s patients at baseline. Pearson’s corre-
lation coefficients (rP) between OPG and hArg (a), OPG and ADMA 
(b), and OPG and the hArg/ADMA molar ratio (c)
981Distinct associations between plasma osteoprotegerin, homoarginine and asymmetric…
1 3
cardiovascular outcome in the population-based Dallas Heart 
Study. Arterioscler Thromb Vasc Biol 34:2501–2507
Atzler D, Appelbaum S, Cordts K, Ojeda FM, Wild PS, Münzel T, 
Blankenberg S, Böger RH, Blettner M, Beutel ME, Pfeiffer N, 
Zeller T, Lackner KJ, Schwedhelm E (2016) Reference intervals 
of plasma homoarginine from the German Gutenberg Health 
Study. Clin Chem Lab Med 54:1231–1237
Bjerre M, Hilden J, Kastrup J, Skoog M, Hansen JF, Kolmos HJ, Jensen 
GB, Kjøller E, Winkel P, Flyvbjerg A, Gluud C, Group CT (2014) 
Osteoprotegerin independently predicts mortality in patients with 
stable coronary artery disease: the CLARICOR trial. Scand J Clin 
Lab Invest 74:657–664
Böger RH, Maas R, Schulze F, Schwedhelm E (2009) Asymmetric 
dimethylarginine (ADMA) as a prospective marker of cardio-
vascular disease and mortality—an update on patient popula-
tions with a wide range of cardiovascular risk. Pharmacol Res 
60:481–487
Choe CU, Atzler D, Wild PS, Carter AM, Böger RH, Ojeda F, Simova 
O, Stockebrand M, Lackner K, Nabuurs C, Marescau B, Streichert 
T, Müller C, Lüneburg N, De Deyn PP, Benndorf RA, Baldus S, 
Gerloff C, Blankenberg S, Heerschap A et al (2013) Homoarginine 
levels are regulated by l-arginine:glycine amidinotransferase and 
affect stroke outcome: results from human and murine studies. 
Circulation 128:1451–1461
Drechsler C, Kollerits B, Meinitzer A, März W, Ritz E, König P, Neyer 
U, Pilz S, Wanner C, Kronenberg F, Group MS (2013) Homoar-
ginine and progression of chronic kidney disease: results from 
the Mild to Moderate Kidney Disease Study. PLoS One 8:e63560
Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Böger SM, 
Haller H, Ritz E (2005) Asymmetric dimethylarginine and pro-
gression of chronic kidney disease: the mild to moderate kidney 
disease study. J Am Soc Nephrol 16:2456–2461
Frenay AR, Kayacelebi AA, Beckmann B, Soedamah-Muhtu SS, de 
Borst MH, van den Berg E, van Goor H, Bakker SJ, Tsikas D 
(2015) High urinary homoarginine excretion is associated with 
low rates of all-cause mortality and graft failure in renal transplant 
recipients. Amino Acids 47:1827–1836
Hanff E, Lützow M, Kayacelebi AA, Finkel A, Maassen M, Yanchev 
GR, Haghikia A, Bavendiek U, Buck A, Lücke T, Maassen N, 
Tsikas D (2017) Simultaneous GC-ECNICI-MS measurement 
of nitrite, nitrate and creatinine in human urine and plasma in 
clinical settings. J Chromatogr B Anal Technol Biomed Life Sci 
1047:207–214
Hanff E, Ruben S, Kreuzer M, Bollenbach A, Kayacelebi AA, Das AM, 
von Versen-Höynck F, von Kaisenberg C, Haffner D, Ückert S, 
Tsikas D (2019) Development and validation of GC–MS methods 
for the comprehensive analysis of amino acids in plasma and urine 
and applications to the HELLP syndrome and pediatric kidney 
transplantation: evidence of altered methylation, transamidination, 
and arginase activity. Amino Acids 51:529–547
Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmus-
sen LM (2008) Plasma osteoprotegerin levels predict cardiovas-
cular and all-cause mortality and deterioration of kidney func-
tion in type 1 diabetic patients with nephropathy. Diabetologia 
51:2100–2107
Kayacelebi AA, Beckmann B, Gutzki FM, Jordan J, Tsikas D (2014a) 
GC–MS and GC–MS/MS measurement of the cardiovascular 
risk factor homoarginine in biological samples. Amino Acids 
46:2205–2217
Kayacelebi AA, Nguyen TH, Neil C, Horowitz JD, Jordan J, Tsikas D 
(2014b) Homoarginine and 3-nitrotyrosine in patients with takot-
subo cardiomyopathy. Int J Cardiol 173:546–547
Kayacelebi AA, Minović I, Hanff E, Frenay AS, de Borst MH, Feelisch 
M, van Goor H, Bakker SJL, Tsikas D (2017) Low plasma 
homoarginine concentration is associated with high rates of 
all-cause mortality in renal transplant recipients. Amino Acids 
49:1193–1202
Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, 
Santer P, Smolen J, Poewe W, Willeit J (2004) Osteoprotegerin 
is a risk factor for progressive atherosclerosis and cardiovascular 
disease. Circulation 109:2175–2180
Kleber ME, Seppälä I, Pilz S, Hoffmann MM, Tomaschitz A, Oksala 
N, Raitoharju E, Lyytikäinen LP, Mäkelä KM, Laaksonen R, 
Kähönen M, Raitakari OT, Huang J, Kienreich K, Fahrleitner-
Pammer A, Drechsler C, Krane V, Boehm BO, Koenig W, Wan-
ner C et al (2013) Genome-wide association study identifies 
3 genomic loci significantly associated with serum levels of 
homoarginine: the AtheroRemo Consortium. Circ Cardiovasc 
Genet 6:505–513
Kuźniewski M, Fedak D, Dumnicka P, Stępień E, Kuśnierz-Cabala 
B, Cwynar M, Sułowicz W (2016) Osteoprotegerin and osteo-
protegerin/TRAIL ratio are associated with cardiovascular dys-
function and mortality among patients with renal failure. Adv 
Med Sci 61:269–275
Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita 
K, Gansevoort RT, Kasiske BL, Eckardt KU (2011) The defini-
tion, classification, and prognosis of chronic kidney disease: a 
KDIGO controversies conference report. Kidney Int 80:17–28
Lewis JR, Lim WH, Zhu K, Wong G, Dhaliwal SS, Lim EM, Ueland 
T, Bollerslev J, Prince RL (2014) Elevated osteoprotegerin pre-
dicts declining renal function in elderly women: a 10-year pro-
spective cohort study. Am J Nephrol 39:66–74
Lewis JR, Lim WH, Ueland T, Wong G, Zhu K, Lim EM, Bollerslev 
J, Prince RL (2015) Elevated circulating osteoprotegerin and 
renal dysfunction predict 15-year cardiovascular and all-cause 
mortality: a prospective study of elderly women. PLoS One 
10:e0134266
Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF, 
Rong J, Corey D, Hoffmann U, Fox CS, Vasan RS, Benjamin EJ, 
O’Donnell CJ, Kathiresan S (2010) Biomarkers of the osteopro-
tegerin pathway: clinical correlates, subclinical disease, incident 
cardiovascular disease, and mortality. Arterioscler Thromb Vasc 
Biol 30:1849–1854
März W, Meinitzer A, Drechsler C, Pilz S, Krane V, Kleber ME, Fis-
cher J, Winkelmann BR, Böhm BO, Ritz E, Wanner C (2010) 
Homoarginine, cardiovascular risk, and mortality. Circulation 
122:967–975
Mesquita M, Demulder A, Damry N, Mélot C, Wittersheim E, Willems 
D, Dratwa M, Bergmann P (2009) Plasma osteoprotegerin is an 
independent risk factor for mortality and an early biomarker of 
coronary vascular calcification in chronic kidney disease. Clin 
Chem Lab Med 47:339–346
Morisawa T, Nakagomi A, Kohashi K, Kosugi M, Kusama Y, Atarashi 
H, Shimizu W (2015) Osteoprotegerin is associated with endothe-
lial function and predicts early carotid atherosclerosis in patients 
with coronary artery disease. Int Heart J 56:605–612
Pilz S, Teerlink T, Scheffer PG, Meinitzer A, Rutters F, Tomaschitz 
A, Drechsler C, Kienreich K, Nijpels G, Stehouwer CD, März W, 
Dekker JM (2014) Homoarginine and mortality in an older popu-
lation: the Hoorn study. Eur J Clin Invest 44:200–208
Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C 
(2005) Asymmetrical dimethylarginine predicts progression to 
dialysis and death in patients with chronic kidney disease: a com-
peting risks modeling approach. J Am Soc Nephrol 16:2449–2455
Ravani P, Maas R, Malberti F, Pecchini P, Mieth M, Quinn R, Tripepi 
G, Mallamaci F, Zoccali C (2013) Homoarginine and mortality 
in pre-dialysis chronic kidney disease (CKD) patients. PLoS One 
8:e72694
Røysland R, Bonaca MP, Omland T, Sabatine M, Murphy SA, Scirica 
BM, Bjerre M, Flyvbjerg A, Braunwald E, Morrow DA (2012) 
982 E. Wieczorek-Surdacka et al.
1 3
Osteoprotegerin and cardiovascular mortality in patients with 
non-ST elevation acute coronary syndromes. Heart 98:786–791
Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, 
Kastelein JJ, Khaw KT, Boekholdt SM (2009) Osteoprotegerin 
and soluble receptor activator of nuclear factor-kappaB ligand and 
risk for coronary events: a nested case-control approach in the pro-
spective EPIC-Norfolk population study 1993–2003. Arterioscler 
Thromb Vasc Biol 29:975–980
Thum T, Tsikas D, Stein S, Schultheiss M, Eigenthaler M, Anker SD, 
Poole-Wilson PA, Ertl G, Bauersachs J (2005) Suppression of 
endothelial progenitor cells in human coronary artery disease 
by the endogenous nitric oxide synthase inhibitor asymmetric 
dimethylarginine. J Am Coll Cardiol 46:1693–1701
Tomaschitz A, Meinitzer A, Pilz S, Rus-Machan J, Genser B, Drechsler 
C, Grammer T, Krane V, Ritz E, Kleber ME, Pieske B, Kraigher-
Krainer E, Fahrleitner-Pammer A, Wanner C, Boehm BO, März W 
(2014) Homoarginine, kidney function and cardiovascular mortal-
ity risk. Nephrol Dial Transplant 29:663–671
Tschiderer L, Willeit J, Schett G, Kiechl S, Willeit P (2017) Osteopro-
tegerin concentration and risk of cardiovascular outcomes in nine 
general population studies: literature-based meta-analysis involv-
ing 26,442 participants. PLoS One 12:e0183910
Tschiderer L, Klingenschmid G, Nagrani R, Willeit J, Laukkanen JA, 
Schett G, Kiechl S, Willeit P (2018) Osteoprotegerin and car-
diovascular events in high-risk populations: Meta-Analysis of 19 
prospective studies involving 27,450 participants. J Am Heart 
Assoc 7:e009012
Tsikas D (2017) Assessment of lipid peroxidation by measuring malon-
dialdehyde (MDA) and relatives in biological samples: analytical 
and biological challenges. Anal Biochem 524:13–30
Tsikas D, Kayacelebi AA (2014) Do homoarginine and asymmetric 
dimethylarginine act antagonistically in the cardiovascular sys-
tem? Circ J 78:2094–2095
Tsioufis C, Aggelis A, Dimitriadis K, Thomopoulos C, Kasiakogias 
A, Tzamou V, Kyvelou SM, Mikhailidis DP, Papademetriou V, 
Stefanadis C (2011) Relationships of osteoprotegerin with albu-
minuria and asymmetric dimethylarginine in essential hyperten-
sion: integrating vascular dysfunction. Expert Opin Ther Targets 
15:1347–1353
Venuraju SM, Yerramasu A, Corder R, Lahiri A (2010) Osteoprote-
gerin as a predictor of coronary artery disease and cardiovascular 
mortality and morbidity. J Am Coll Cardiol 55:2049–2061
Yilmaz MI, Siriopol D, Saglam M, Unal HU, Karaman M, Gezer M, 
Kilinc A, Eyileten T, Guler AK, Aydin İ, Vural A, Oguz Y, Covic 
A, Ortiz A, Kanbay M (2016) Osteoprotegerin in chronic kidney 
disease: associations with vascular damage and cardiovascular 
events. Calcif Tissue Int 99:121–130
Zinellu A, Paliogiannis P, Carru C, Mangoni AA (2018) Homoarginine 
and all-cause mortality: a systematic review and meta-analysis. 
Eur J Clin Invest 48:e12960
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
